Firebrick Pharma : Investor Presentation - Euroz Hartleys Rottnest Conference

only
use	INVESTOR PRESENTATION
ersonal	11 MARCH 2022
EUROZ HARTLEYS ROTTNEST ISLAND INSTITUTIONAL CONFERENCE
FIR EB R IC K PHA R MA . C O M	INVESTO R PR ESENTA TIO N		MA R C H 2022

IMPORTANT NOTICE AND DISCLAIMER

ersonal use only

This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared as of its date, and remains subject to change without notice. This presentation has been provided to you solely for the purpose of giving you background information about Firebrick Pharma Limited (Firebrick). This presentation is intended only for those persons to whom it is delivered personally by or on behalf of Firebrick. By attending this presentation, you represent and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are outside Australia, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this document and any copies and do not provide this document to any other person. This presentation is strictly confidential and is intended for the exclusive benefit of the person to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of Firebrick. The recipient shall not disclose any of the information contained in this presentation to any other person without the prior written consent of Firebrick, which may be withheld in its absolute discretion.

No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. Neither Firebrick, its related bodies corporate, shareholders or affiliates, nor any of their respective officers, directors, employees, related bodies corporate, affiliates, agents or advisers makes any representations or warranties that this presentation is complete or that it contains all material information about Firebrick or which a prospective investor or purchaser may require in evaluating a possible investment in Firebrick or an acquisition of its shares. To the maximum extent permitted by law, none of those persons accept any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based upon information known and assumptions made as of the date of this presentation. Forward looking statements can generally be identified by the use of forward looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, and guidance or outlook on, clinical trials, required regulatory approvals, future earnings or financial position or performance are also forward looking statements. These statements are subject to internal and external risks and uncertainties that may have a material effect on future business. Actual results may differ materially from any future results or performance expressed, predicted or implied by the statements contained in this presentation. As such, undue reliance should not be placed on any forward looking statement. Past performance is not necessarily a guide to future performance. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future. No person is under any obligation to update this presentation at any time after its release to you.

The provision of this presentation is not a representation to you or any other person that an offer of securities will be made. Any prospective transaction would be undertaken solely on the basis of disclosure documentation prepared in accordance with applicable securities laws and regulations. The information presented in this presentation may differ materially in both content and presentation from that presented in any disclosure document prepared in connection with any prospective transaction. Firebrick reserves the right to alter the information contained in this presentation in any disclosure document prepared in respect of any prospective transaction from the form of this presentation accordingly.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in Firebrick and neither this presentation nor any of the information contained herein shall form the basis of any contract or commitment. In particular, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. This presentation may not be reproduced or redistributed to any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party without the prior approval of Firebrick. All references to dollars, cents or $ in this presentation are to Australian currency, unless otherwise stated.

In receiving this presentation, each recipient agrees to the foregoing terms and conditions.

INVESTO R PR ESENTA TIO N		2

FIREBRICK IPO STORY

Australian Pharmaceutical Innovator Focused on Infectious Disease

Breakthrough Product: Nasodine

only	Kills1 the viruses that cause colds
First-in-class nasal spray medicine that
targets the viral cause of the common cold
Acts in the nose, where colds start
use	Same active as BETADINE® products2
Povidone-iodine(PVP-I) widely used as a gargle,
now in a nasal spray, Nasodine® Nasal Spray
Patent protected to 2034/2035 as a
	treatment or preventative for common cold
	Pandemic Potential
	Kills SARS-CoV-2in vitro
	Phase 2 COVID-19 clinical trial in 2022
	US Patent granted for use in COVID-19

ersonal1, For viruses, the term "kill" indicates elimination of viral infectivity. In in vitro studies, Nasodine has been shown to eliminate the infectivity of representative strains of all vi uses known to cause respiratory infections, such as the common cold.

2 B tadine® is a registered trademark of Mundipharma AG and in Australia is now licensed to Sanofi Aventis. There is no association between Firebrick, Mundipharma, Sanofi Aventis or the Betadine brand. Povidone-iodine is widely available and can be supplied and used without license from Mundipharma or any other party.

Late-stage Biopharma story

Nasodine completed Phase 1-3 trials

Second Phase 3 trial in 2022

Manufacturing ready

Potential near-term regulatory approval

Large Addressable Market

Global potential

Billions of colds each year worldwide

Potential for broad market adoption

Proven Successful Team

Firebrick founder launched Betadine® Gargle2

Track record of success on ASX

Experienced management and board

PHASE 3	INVESTO R PR ESENTA TIO N		3

IPO PERFORMANCE

Listed on ASX as 'FRE' on 28 January 2022

ersonal use only

Extensive media coverage

High performance in bear market

IPO: $0.20 x 169m shares = $34m m/cap

52 million shares traded in first 5 days

5-day VWAP to 8 March = $0.43

still up >100% on IPO price; m/cap ~ $70m

Shareholders increased from 400 -> 4,600

The Firebrick appeal

Many early investors were Australian doctors who believe in the product concept

Technology story is easy to comprehend:

kills viruses in the nose to treat colds

Unprecedent public awareness of the role of viruses in respiratory illness

The common cold is a huge global market - first nasal spray medicine targeting viral cause

Perceived low risk Phase 3 trial with

potential for near-term approval

Upside of potential COVID-19 use and role in future pandemics

Management calibre & track record on ASX

Support of Euroz Hartleys - sole Lead Manager

INVESTO R PR ESENTA TIO N

4

NASODINE® NASAL SPRAY

only	Australian breakthrough that could be the world's firstapproved
nasal medicine that actually targets the viral cause of colds
Contains povidone-iodine(PVP-I) 0.5%
	• In a proprietary formulation, safe for use on nasal tissue1
use	Kills2 all respiratory viruses
• PVP-I releases free iodine that kills all respiratory viruses
• Virucidal - leads to permanent loss of viral infectivity
• Non-selective - viral resistance has not been reported to PVP-I

Strong patent position; granted patents in the U.S, EU, AU + others

• Protect use of intranasal PVP-I as treatment/preventative for common cold (2034/35) and use in pandemic viral diseases (2040)

				Nasodine® Nasal Spray ("Nasodine") is not yet approved for sale
ersonal				• 2nd Phase 3 trial planned for 2022 prior to re-submission to TGA
	NASODINE		• Potential for approval in 2022 if Section 60 appeal succeeds
		PACKAGING AS
		SUBMITTED TO
		TGA
1 At low concentrations (e.g., 0.5%) and in an appropriate formulation
2, For viruses, the term "kill" indicates elimination of viral infectivity. In in vitro studies, Nasodine has been shown to eliminate the infectivity	INVESTO R PR ESENTA TIO N		5
of r presentative strains of all viruses known to cause respiratory infections, such as the common cold.